Enrico Vizzardi1,2, Edoardo Sciatti3, Ivano Bonadei3, Antonio D'Aloia3, Lamia Tartière-Kesri4,5, Jean-Michel Tartière5,6, Alain Cohen-Solal7,6, Marco Metra3. 1. Section of Cardiovascular Diseases, Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, University of Study of Brescia, Brescia, Italy. enrico.vizzardi@tin.it. 2. , Piazzale Spedali Civili 1, 25123, Brescia, Italy. enrico.vizzardi@tin.it. 3. Section of Cardiovascular Diseases, Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, University of Study of Brescia, Brescia, Italy. 4. Cardiac Rehabilitation, Léon Bérard Hospital, Hyères, France. 5. Cardiology Department, Sainte Musse Hospital, Toulon, France. 6. INSERM U942, Paris, France. 7. Cardiology Department, Lariboisière Hospital and Denis Diderot University, Paris, France.
Abstract
BACKGROUND: Several studies demonstrated that mineralocorticoid receptor antagonists (MRAs) are able to prevent myocardial and vascular fibrosis, and left ventricular (LV) remodeling in patients with systolic chronic heart failure (HF) and mild symptoms. Ventricular-arterial coupling (VAC) should be influenced by anti-fibrotic interventions. We have assessed the effects of spironolactone on VAC and its components, aortic elastance (Ea) and end-systolic LV elastance (Ees), in patients with HF. METHODS AND RESULTS: Changes from baseline in VAC were compared between 65 patients treated with spironolactone and 32 controls not receiving MRAs. All patients had HF, reduced LVEF with reduced LV ejection fraction (LVEF) and New York Heart Association (NYHA) functional class I-II symptoms, and underwent transthoracic echocardiography at baseline and after 6 months. VAC was estimated by the modified single-beat method as Ea/Ees. Parameters of LV function improved after 6 month treatment with spironolactone with an increase in the LVEF from 34 ± 8 to 39 ± 8 % (p < 0.001). Spironolactone increased Ees from 1.32 ± 0.38 to 1.57 ± 0.42 mmHg/mL (p < 0.001) and reduced VAC from 2.03 ± 0.59 to 1.66 ± 0.31 (p < 0.001), but did not affect Ea and V0 (LV volume at end-systolic pressure of 0 mmHg). No change in any of these parameters occurred in the control group. CONCLUSIONS: 6-month therapy with spironolactone improved VAC mainly through its effect on Ees in patients with mild HF.
BACKGROUND: Several studies demonstrated that mineralocorticoid receptor antagonists (MRAs) are able to prevent myocardial and vascular fibrosis, and left ventricular (LV) remodeling in patients with systolic chronic heart failure (HF) and mild symptoms. Ventricular-arterial coupling (VAC) should be influenced by anti-fibrotic interventions. We have assessed the effects of spironolactone on VAC and its components, aortic elastance (Ea) and end-systolic LV elastance (Ees), in patients with HF. METHODS AND RESULTS: Changes from baseline in VAC were compared between 65 patients treated with spironolactone and 32 controls not receiving MRAs. All patients had HF, reduced LVEF with reduced LV ejection fraction (LVEF) and New York Heart Association (NYHA) functional class I-II symptoms, and underwent transthoracic echocardiography at baseline and after 6 months. VAC was estimated by the modified single-beat method as Ea/Ees. Parameters of LV function improved after 6 month treatment with spironolactone with an increase in the LVEF from 34 ± 8 to 39 ± 8 % (p < 0.001). Spironolactone increased Ees from 1.32 ± 0.38 to 1.57 ± 0.42 mmHg/mL (p < 0.001) and reduced VAC from 2.03 ± 0.59 to 1.66 ± 0.31 (p < 0.001), but did not affect Ea and V0 (LV volume at end-systolic pressure of 0 mmHg). No change in any of these parameters occurred in the control group. CONCLUSIONS: 6-month therapy with spironolactone improved VAC mainly through its effect on Ees in patients with mild HF.
Authors: Lawrence G Rudski; Wyman W Lai; Jonathan Afilalo; Lanqi Hua; Mark D Handschumacher; Krishnaswamy Chandrasekaran; Scott D Solomon; Eric K Louie; Nelson B Schiller Journal: J Am Soc Echocardiogr Date: 2010-07 Impact factor: 5.251
Authors: Karl Swedberg; Faiez Zannad; John J V McMurray; Henry Krum; Dirk J van Veldhuisen; Harry Shi; John Vincent; Bertram Pitt Journal: J Am Coll Cardiol Date: 2012-05-01 Impact factor: 24.094
Authors: Sherif F Nagueh; Christopher P Appleton; Thierry C Gillebert; Paolo N Marino; Jae K Oh; Otto A Smiseth; Alan D Waggoner; Frank A Flachskampf; Patricia A Pellikka; Arturo Evangelista Journal: J Am Soc Echocardiogr Date: 2009-02 Impact factor: 5.251
Authors: N B Schiller; P M Shah; M Crawford; A DeMaria; R Devereux; H Feigenbaum; H Gutgesell; N Reichek; D Sahn; I Schnittger Journal: J Am Soc Echocardiogr Date: 1989 Sep-Oct Impact factor: 5.251
Authors: Wojciech Kosmala; Monika Przewlocka-Kosmala; Hanna Szczepanik-Osadnik; Andrzej Mysiak; Thomas H Marwick Journal: Heart Date: 2013-01-23 Impact factor: 5.994
Authors: W von Scheidt; C Zugck; M Pauschinger; R Hambrecht; O Bruder; A Hartmann; M Rauchhaus; R Zahn; J Brachmann; U Tebbe; T Neumann; R H Strasser; M Böhm; S Störk; M Hochadel; P Heidemann; J Senges Journal: Clin Res Cardiol Date: 2014-07-23 Impact factor: 5.460
Authors: Christoph Sinning; Francisco Ojeda; Philipp S Wild; Renate B Schnabel; Michael Schwarzl; Sevenai Ohdah; Karl J Lackner; Norbert Pfeiffer; Matthias Michal; Maria Blettner; Thomas Munzel; Tibor Kempf; Kai C Wollert; Kari Kuulasmaa; Stefan Blankenberg; Veikko Salomaa; Dirk Westermann; Tanja Zeller Journal: Clin Res Cardiol Date: 2016-12-21 Impact factor: 5.460
Authors: Mark A Lawson; David E Hansen; Deepak K Gupta; Susan P Bell; Douglas W Adkisson; Ravinder R Mallugari; Douglas B Sawyer; Henry Ooi; Marvin W Kronenberg Journal: ESC Heart Fail Date: 2021-01-05